Results 171 to 180 of about 3,069,601 (247)

Visualizing Baseline Eligibility Across Locally Advanced or Metastatic Urothelial Cancer Trials and Real-World Cohorts. [PDF]

Int J Urol
Ichiyama T, Narita T, Sato H, Sekine Y, Shinohara M, Kawashima Y, Kobayashi M, Numakura K, Mikami J, Fujita N, Okamoto T, Yamamoto H, Yoneyama T, Narita S, Sato S, Habuchi T, Ohyama C, Hatakeyama S.   +17 more
europepmc   +1 more source

Merkel cell carcinoma: an updated guide for pathologists

Histopathology, EarlyView.
Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma for which the differential diagnosis can include other small cell malignancies (especially metastatic small cell carcinoma) or cutaneous carcinoma. Morphologic and immunophenotypic aberrancies in MCC can increase diagnostic challenge.
Paul W. Harms
wiley   +1 more source

Hybrid grading systems improve progression risk stratification in non‐invasive papillary urothelial carcinoma and support a histomorphological continuum of disease progression

Histopathology, EarlyView.
Hybrid grading systems significantly improve progression‐risk stratification in non‐invasive papillary urothelial carcinoma compared with the WHO 2004/2016 binary classification, with most benefit achieved by a Hybrid 3‐Tier framework. These findings support the existence of a histomorphological continuum of progression risk within the conventional ...
Jane K Nguyen, Marcello P Toscano, Jianbo Li, Sean R Williamson, Christopher G Przybycin, Chia‐Sui Kao, Jonathan L Myles, Kristýna Pivovarčíková, Marián Švajdler, Marek Brousil, Mohamed Eltemamy, Laura Bukavina, Venkatesh Krishnamurthi, Christopher Weight, Rebecca A Campbell, Nima Almassi, Reza Alaghehbandan   +16 more
wiley   +1 more source

A Delphi consensus for implementing genomic testing in unresectable or metastatic urothelial cancer. [PDF]

BJU Int
Hussain SA, Challapalli A, Gill S, Hubank M, Markham H, Tanière P, Wyatt S, Jones R.   +7 more
europepmc   +1 more source

Interleukin‐12: Central Roles in Immune Regulation and Disease Therapy

Immunology &Cell Biology, EarlyView.
IL‐12 levels are tightly regulated to balance effective protective immunity against infections and cancer with the risk of excessive inflammation and autoimmune disease. Both insufficient and excessive IL‐12 activity can therefore be detrimental, highlighting the importance of precisely controlling its production and signaling. ABSTRACT Interleukin‐12 (
Anthi Psoma, Geert van den Bogaart
wiley   +1 more source

Characteristics of Patients With Advanced or Metastatic Urothelial Cancer Unable to Complete Six Cycles Chemotherapy. [PDF]

Cancer Med
Jackson-Spence F, Aspden D, Chauhan V, Diaz S, Graham C, Young M, Nally E, Wells JC, Membribes SC, Ackerman C, Szabados B, Powles T.   +11 more
europepmc   +1 more source

HierAnom‐Path: Zero‐Shot Rare Cancer Detection in Histopathology via Hierarchical Foundation Model Adaptation

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Rare cancers collectively represent 20%–25% of all malignancies yet yield fewer than 50 annotated whole‐slide images (WSIs) per subtype in publicly available archives, rendering supervised deep learning inapplicable. We present HierAnom‐Path, to the best of our knowledge, the first framework for zero‐shot rare cancer anomaly detection in ...
Noora Saleem Jumaah, Mohanad Sameer Jabbar, Saif H. Alwaeli, Noor Ayesha, Mohamed Babiker A. Mohamed, Muhammad I. Khan   +5 more
wiley   +1 more source

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany

International Journal of Cancer, Volume 159, Issue 9, Page 2290-2299, 1 November 2026.
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel, Theresa Lowinus, Patrick Metzger, Rebecca Czurda, Vincent Schipperges, Ulrike Paul, Alessandra Rünger, Julian Kött, Isabel Heidrich, Saskia Lehr, Julia Kühn, Heiko Becker, Cornelius Miething, Martin Werner, Silke Laßmann, Justus Duyster, Tilman Brummer, Ronald Simon, Winfried Alsdorf, Maximilian Christopeit, Carsten Bokemeyer, Kilian Eyerich, Stefan W. Schneider, David Rafei, Melanie Börries, Frank Meiss, Christoffer Gebhardt   +26 more
wiley   +1 more source

β2-integrins as biomarkers in urothelial cancer. [PDF]

PLoS One
Llort Asens M, Khan I, Fagerholm SC.
europepmc   +1 more source

Pseudoprogression During Enfortumab Vedotin Plus Pembrolizumab Therapy in Muscle‐Invasive Bladder Cancer Achieving Pathological Complete Response: A Case Report

IJU Case Reports, Volume 9, Issue 6, November 2026.
ABSTRACT Introduction Enfortumab vedotin plus pembrolizumab has emerged as a standard first‐line therapy for advanced urothelial carcinoma (UC). However, pseudoprogression during this combination remains poorly characterized. Case Presentation A 71‐year‐old man with muscle‐invasive bladder cancer and lymph node metastasis received enfortumab vedotin ...
Yosuke Nakanishi, Yohei Kawashima, Masanao Shinohara, Kazuhisa Hagiwara, Kohei Inui, Kazue Ogawa, Daiji Fujimori, Shingo Moriyama, Hanako Oba, Sato Satoshi   +9 more
wiley   +1 more source